Concepedia

Dose-dependent Tolerability

Dose-Dependent Tolerability is a pharmacological and toxicological concept that denotes the graded capacity of mucosal tissues to withstand adverse effects in response to varying concentrations of an administered agent, where the extent of tolerability is systematically determined by the magnitude of the dose.

207

Publications

12.8K

Citations

1.4K

Authors

509

Institutions

Publications per year

2017–2026

47

Parents

Publications

207

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 763 citations

, , +14

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2002 · 578 citations

, , +17

Botulinum A Toxin Injection as a Treatment for Blepharospasm

Alan B. Scott, R. A. Kennedy, Harrison A. Stubbs · Archives of Ophthalmology · 1985 · 419 citations

, , +14

Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

Qin Ryan, Donna Headlee, Milin Acharya et al. · Journal of Clinical Oncology · 2005 · 414 citations · Full text

, , +16

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study

Ole B. Suhr, Teresa Coelho, Juan Buades et al. · Orphanet Journal of Rare Diseases · 2015 · 322 citations · Full text

, , +17

1–5 of 207

Authors

1.4K

  1. JD
    Jasper Dingemanse

    Actelion (Switzerland), Switzerland

    8 publications · 307 citations

    8

    h-index

  2. PN
    Patricia N. Sidharta

    Actelion (Switzerland), Switzerland

    3 publications · 78 citations

    3

    h-index

  3. RA
    Robert A. Dean

    Eli Lilly (United States), United States

    3 publications · 423 citations

    3

    h-index

  4. CG
    Celedon Gonzales

    Eli Lilly (United States), United States

    3 publications · 423 citations

    3

    h-index

  5. MS
    Martina Sterneck

    Universität Hamburg, Germany

    2 publications · 46 citations

    2

    h-index

1–5 of 1.4K

Institutions

509

  1. Pfizer (United States)

    New York, United States

    9 h-index

    32 publications

    1.5K citations

  2. Actelion (Switzerland)

    Allschwil, Switzerland

    7 h-index

    24 publications

    883 citations

  3. Eli Lilly (United States)

    Indianapolis, United States

    7 h-index

    50 publications

    4.8K citations

  4. University of British Columbia

    Vancouver, Canada

    5 h-index

    7 publications

    798 citations

  5. United States Military Academy

    West Point, United States

    5 h-index

    33 publications

    2K citations

  6. Roche (Switzerland)

    Basel, Switzerland

    5 h-index

    24 publications

    1.7K citations

  7. Novartis (Switzerland)

    Basel, Switzerland

    5 h-index

    25 publications

    1.4K citations

  8. Charité - Universitätsmedizin Berlin

    Berlin, Germany

    5 h-index

    26 publications

    1.2K citations

1–8 of 509

Venues

  1. PubMed

    Repository · 13 publications · 647 citations

    11

    h-index

  2. The Journal of Clinical Pharmacology

    8 publications · 476 citations

    8

    h-index

  3. Journal of Clinical Oncology

    8 publications · 2.2K citations

    8

    h-index

  4. British Journal of Clinical Pharmacology

    BJCP · 7 publications · 185 citations

    7

    h-index

  5. Clinical Neuropharmacology

    5 publications · 512 citations

    5

    h-index

1–5